LM-Kit.NET is an enterprise-grade toolkit designed for seamlessly integrating generative AI into your .NET applications, fully supporting Windows, Linux, and macOS. Empower your C# and VB.NET projects with a flexible platform that simplifies the creation and orchestration of dynamic AI agents.
Leverage efficient Small Language Models for on‑device inference, reducing computational load, minimizing latency, and enhancing security by processing data locally. Experience the power of Retrieval‑Augmented Generation (RAG) to boost accuracy and relevance, while advanced AI agents simplify complex workflows and accelerate development.
Native SDKs ensure smooth integration and high performance across diverse platforms. With robust support for custom AI agent development and multi‑agent orchestration, LM‑Kit.NET streamlines prototyping, deployment, and scalability—enabling you to build smarter, faster, and more secure solutions trusted by professionals worldwide.
Learn more
SciSure is reshaping the future of laboratories worldwide with forward-thinking digital solutions. Our Digital Lab Platform (DLP) unites key tools such as Electronic Lab Notebook (ELN), Laboratory Information Management Systems (LIMS), and advanced technologies like AI and machine learning. Built for seamless compatibility with your lab's hardware and software, the platform enhances flexibility, security, and efficiency. By consolidating and optimizing your research and development workflows within a secure and compliant environment, we help researchers dedicate more time to innovation. Our expert team is committed to supporting you at every stage of your digital lab transformation.
Learn more
Evo 2
Evo 2 represents a cutting-edge genomic foundation model that excels in making predictions and designing tasks related to DNA, RNA, and proteins. It employs an advanced deep learning architecture that allows for the modeling of biological sequences with single-nucleotide accuracy, achieving impressive scaling of both compute and memory resources as the context length increases. With a robust training of 40 billion parameters and a context length of 1 megabase, Evo 2 has analyzed over 9 trillion nucleotides sourced from a variety of eukaryotic and prokaryotic genomes. This extensive dataset facilitates Evo 2's ability to conduct zero-shot function predictions across various biological types, including DNA, RNA, and proteins, while also being capable of generating innovative sequences that maintain a plausible genomic structure. The model's versatility has been showcased through its effectiveness in designing operational CRISPR systems and in the identification of mutations that could lead to diseases in human genes. Furthermore, Evo 2 is available to the public on Arc's GitHub repository, and it is also incorporated into the NVIDIA BioNeMo framework, enhancing its accessibility for researchers and developers alike. Its integration into existing platforms signifies a major step forward for genomic modeling and analysis.
Learn more
NVIDIA BioNeMo
BioNeMo is a cloud service and framework for drug discovery that leverages AI, built on NVIDIA NeMo Megatron, which enables the training and deployment of large-scale biomolecular transformer models. This service features pre-trained large language models (LLMs) and offers comprehensive support for standard file formats related to proteins, DNA, RNA, and chemistry, including data loaders for SMILES molecular structures and FASTA sequences for amino acids and nucleotides. Additionally, users can download the BioNeMo framework for use on their own systems. Among the tools provided are ESM-1 and ProtT5, both transformer-based protein language models that facilitate the generation of learned embeddings for predicting protein structures and properties. Furthermore, the BioNeMo service will include OpenFold, an advanced deep learning model designed for predicting the 3D structures of novel protein sequences, enhancing its utility for researchers in the field. This comprehensive offering positions BioNeMo as a pivotal resource in modern drug discovery efforts.
Learn more
